Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandan HealthcareNSE:CHANDAN -4.01%17 Return-on-Tangible-Equity is 13.57% as of Dec. 2025, which is 39% below its 10-year median of 22.24. GuruFocus rates NSE:CHANDAN with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Chandan Healthcare ranks better than 68.06% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Chandan Healthcare's annualized net income for the quarter that ended in Dec. 2025 was ₹182 Mil. Chandan Healthcare's average shareholder tangible equity for the quarter that ended in Dec. 2025 was ₹1,338 Mil. Therefore, Chandan Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 13.57%.
The historical rank and industry rank for Chandan Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
NSE:CHANDAN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.67 Med: 22.24 Max: 54.56
Current: 10.5
During the past 4 years, Chandan Healthcare's highest Return-on-Tangible-Equity was 54.56%. The lowest was -5.67%. And the median was 22.24%.
NSE:CHANDAN's Return-on-Tangible-Equity is ranked better than 68.06% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs NSE:CHANDAN: 10.50
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Chandan Healthcare Return-on-Tangible-Equity Related Terms
Chandan Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Chandan Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CHANDAN vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Chandan Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandan Healthcare Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chandan Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Chandan Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.57% mean?
Chandan Healthcare (NSE:CHANDAN) has a Return-on-Tangible-Equity of 13.57% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chandan Healthcare and its competitors. This is 39% below median its historical median of 22.24. According to the industry distribution chart, Chandan Healthcare ranks #61 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 31.9%.
Is Chandan Healthcare's Return-on-Tangible-Equity too high?
Chandan Healthcare's current Return-on-Tangible-Equity of 13.57% is 39% below median its 10-year median of 22.24. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.07. Chandan Healthcare's value of 13.57% is 19285.7% above this industry median. Based on the distribution chart, Chandan Healthcare ranks #61 out of 191 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Chandan Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Chandan Healthcare's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Chandan Healthcare ranks #61 out of 191 companies for Return-on-Tangible-Equity. This puts Chandan Healthcare in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.07. Chandan Healthcare's value of 13.57% is 19285.7% above this benchmark. While the company's 10-year median is 22.24 vs. the industry median of 0.07, Chandan Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandan Healthcare's current Return-on-Tangible-Equity of 13.57% is 19285.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Chandan Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandan Healthcare's current Return-on-Tangible-Equity is 13.57%, which is 39% below median its own 10-year median of 22.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandan Healthcare stock overvalued right now?
Chandan Healthcare (NSE:CHANDAN) has a current Return-on-Tangible-Equity of 13.57%. The current Return-on-Tangible-Equity is 13.57%, which is 39% below median its 10-year median of 22.24 and 19285.7% above the Medical Diagnostics & Research industry median of 0.07. Chandan Healthcare's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Chandan Healthcare (NSE:CHANDAN), the current Return-on-Tangible-Equity is 13.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chandan Healthcare Ltd operates laboratories that offer comprehensive pathological investigations. Its services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, it provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. The company operates single reportable business segment that is Diagnostics Services.
17GF Score
Get the complete analysis for NSE:CHANDAN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CHANDAN has been successfully added to your 
